Nonsteroidal MR Antagonism in PA: Clinical Outcomes and Unanswered Questions

Overview

Journal Hypertens Res

Specialty Cardiology & Vascular Diseases

Date 2024 Nov 15

PMID 39543423

Authors

Daigoro Hirohama

Shigeru Shibata

Affiliations

Soon will be listed here.

References

Milliez P, Girerd X, Plouin P, Blacher J, Safar M, Mourad J . Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005; 45(8):1243-8. DOI: 10.1016/j.jacc.2005.01.015. View

Funder J, Carey R, Mantero F, Murad M, Reincke M, Shibata H . The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016; 101(5):1889-916. DOI: 10.1210/jc.2015-4061. View

Saiki A, Otsuki M, Tamada D, Kitamura T, Mukai K, Yamamoto K . Increased Dosage of MRA Improves BP and Urinary Albumin Excretion in Primary Aldosteronism With Suppressed Plasma Renin. J Endocr Soc. 2021; 6(1):bvab174. PMC: 8664755. DOI: 10.1210/jendso/bvab174. View

Karashima S, Yoneda T, Kometani M, Ohe M, Mori S, Sawamura T . Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism. Hypertens Res. 2015; 39(3):133-7. DOI: 10.1038/hr.2015.129. View

Hundemer G, Curhan G, Yozamp N, Wang M, Vaidya A . Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2017; 6(1):51-59. PMC: 5953512. DOI: 10.1016/S2213-8587(17)30367-4. View

Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S . Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study). Hypertension. 2019; 75(1):51-58. DOI: 10.1161/HYPERTENSIONAHA.119.13569. View

Uchida H, Nakajima H, Hashimoto M, Nakamura A, Nunoue T, Murakami K . Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study. Adv Ther. 2022; 39(11):5158-5175. PMC: 9449923. DOI: 10.1007/s12325-022-02294-z. View

Yoshida Y, Fujiwara M, Kinoshita M, Sada K, Miyamoto S, Ozeki Y . Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism. Hypertens Res. 2023; 47(1):157-167. DOI: 10.1038/s41440-023-01412-w. View

Fujimoto M, Watanabe S, Igarashi K, Ruike Y, Ishiwata K, Naito K . Antihypertensive Effects of Esaxerenone in Older Patients with Primary Aldosteronism. Int J Hypertens. 2023; 2023:6453933. PMC: 9873463. DOI: 10.1155/2023/6453933. View

10.

Brown N . Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013; 9(8):459-69. PMC: 3922409. DOI: 10.1038/nrneph.2013.110. View

11.

Shibata S, Fujita T . Mineralocorticoid receptors in the pathophysiology of chronic kidney diseases and the metabolic syndrome. Mol Cell Endocrinol. 2011; 350(2):273-80. DOI: 10.1016/j.mce.2011.07.018. View

12.

Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H . Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008; 14(12):1370-6. DOI: 10.1038/nm.1879. View

13.

Hirohama D, Nishimoto M, Ayuzawa N, Kawarazaki W, Fujii W, Oba S . Activation of Rac1-Mineralocorticoid Receptor Pathway Contributes to Renal Injury in Salt-Loaded Mice. Hypertension. 2021; 78(1):82-93. DOI: 10.1161/HYPERTENSIONAHA.121.17263. View

14.

Abedini A, Sanchez-Navaro A, Wu J, Klotzer K, Ma Z, Poudel B . Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists. J Clin Invest. 2023; 134(1). PMC: 10760974. DOI: 10.1172/JCI157165. View